Ulcerative colitis is a chronic condition characterized by inflammation and ulcers in the colon. Research is ongoing to expand treatment options. A study published in the New England Journal of ...
Takeda presented promising data on its ulcerative colitis and Crohn’s disease drug Entyvio at the World Congress of Gastroenterology at ACG2017, Oct. 13 to Oct. 18 in Orlando, Fla. The data suggests ...
Stocktwits on MSN
Why is ALVO stock rising pre-market today?
Alvotech stated that it designed the study to evaluate the safety, tolerability, and immunogenicity profiles of AVT80 and ...
AGA living guideline recommends patients start advanced therapies early in their disease course rather than gradual step-up treatment approach. “Since the first biologic treatment for ulcerative ...
Itolizumab demonstrated clinical efficacy after 12 weeks of treatment, achieving a clinical remission rate of 23.3% compared to 20.0% for adalimumab and 10.0% for placebo Itolizumab achieved key ...
Ferring Pharmaceuticals today announces results from the OPTIMISE study showing the first real-world evidence of the effectiveness of a treat-to-target (T2T) approach based on faecal calprotectin (FC) ...
PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced the Phase 2 LATTICE-UC study evaluating deucravacitinib, a first-in-class, oral, selective tyrosine kinase 2 (TYK2) ...
On Tuesday, the U.S. Food and Drug Administration (FDA) approved Johnson & Johnson’s (NYSE:JNJ) Simponi (golimumab) for children with moderately to severely active ulcerative colitis (UC) who weigh at ...
Floris de Voogd, MD; Elsa A. van Wassenaer, MD; Aart Mookhoek, MD, PhD; Steven Bots, MD; Sara van Gennep, MD; Mark Löwenberg, MD, PhD; Geert R. D’Haens, MD, PhD ...
The MarketWatch News Department was not involved in the creation of this content. Ulcerative Colitis Market Poised for Strong Expansion During the Forecast Period (2025-2034) Driven by Biologic and ...
Intestinal ultrasound (IUS) is non-invasive, cost-effective, and accurate to determine disease activity in ulcerative colitis (UC). In this study, we prospectively evaluated IUS for treatment response ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results